Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Hus, Iwona ^a   Bojarska Junak, Agnieszka ^a   Chocholska, Sylwia ^a   Tomczak, Waldemar ^a   Woś, Justyna ^a   Dmoszyńska, Anna ^a   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 17; MESSENGER RNA; PROTEIN KINASE ZAP 70; RITUXIMAB; TUMOR NECROSIS FACTOR;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD; BONE MARROW; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CELLULAR SECRETION; CHROMOSOME 11Q; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; GENE DELETION; HUMAN; IMMUNE STATUS; KARYOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NATURAL KILLER T CELL; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; TH17 CELL; TH2 CELL; TUMOR IMMUNITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GENE EXPRESSION; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-17; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TREATMENT OUTCOME; VIDARABINE;

EID: 84891401465     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078091     Document Type: Article

References (44)

1. Furman RR (2010) Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010: 77-81.
2. Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, et al. (2006) Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 108: 2950-2956.
3. Mellstedt H, Choudhury A (2006) T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 55: 210-220.
4. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, et al. (2008) Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 141: 607-614.
5. Scrivener S, Goddard RV, Kaminski ER, Prentice AG (2003). Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 44: 383-389.
6. Podhorecka M, Dmoszynska A, Rolinski J, Wasik E (2002) T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia-the three-color flow cytometry analysis. Leuk Res 26: 657-660.
7. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
8. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
9. Beyer M, Schultze JL (2009) Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 15: 1879-1892.
10. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, et al. (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025.
11. D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, et al. (2011) Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35: 363-368.
12. Gaffen SL (2008) An overview of IL-17 function and signaling. Cytokine 43: 402-407.
13. Khader SA, Gaffen SL, Kolls JK (2009) Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2: 403-411.
14. Gaffen SL (2009) The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 11: 365-370.
15. Ji Y, Zhang W (2010) Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 59: 979-987.
16. Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175.
17. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, et al. (2012) Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97: 599-607.
18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. (2008) International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
19. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, et al. (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234.
20. Bojarska-Junak A, Rolinski J, Wasik-Szczepanek E, Kaluzny Z, Dmoszynska A (2002) Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia. Haematologica 87: 490-499.
21. Hus I, Podhorecka M, Bojarska-Junak A, Rolinski J, Schmitt M, et al. (2006). The clinical significance of ZAP-70 and CD38 expression in B cell chronic lymphocytic leukaemia. Ann Oncol 17: 683-690.
22. Zhou P, Sha H, Zhu J (2010) The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res 38: 611-619.
23. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
24. Wang J, Cai D, Ma B, Wu G, Wu J (2011) Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. J Int Med Res 39: 691-701.
25. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, et al. (2010) Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101: 1947-1954.
26. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, et al. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989.
27. Liu J, Duan Y, Cheng X, Chen X, Xie W, et al. (2011) IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407: 348-354.
28. Wu C, Wang S, Wang F, Chen Q, Peng S, et al. (2009) Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 158: 199-204.
29. Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, et al. (2009) IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 145: 64-72.
30. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, et al. (2010) Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115: 5385-5392.
31. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, et al. (2011) Th17 cells in cancer: help or hindrance? Carcinogenesis 32: 643-649.
32. Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10: 248-256.
33. Jadidi-Niaragh F, Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi SM, et al. (2013) Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumour Biol 34: 929-940.
34. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97: 807-812.
35. Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F (2013) Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. Haematologica 98: 376-384.
36. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, et al. (2011) CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 12: 77.
37. de Jong E, Suddason T, Lord GM (2010) Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. Clin Exp Immunol 159: 148-158.
38. Lech-Maranda E, Grzybowska-Izydorczyk O, Wyka K, Mlynarski W, Borowiec M, et al. (2012) Serum tumor necrosis factor-a and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Arch Immunol Ther Exp 60: 477-486.
39. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, et al. (1992) Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176: 1319-1326.
40. Podhorecka M (2004) Apoptosis in pathogenesis of B-cell chronic lymphocytic leukemia. Postepy Hig Med Dosw 58: 236-242.
41. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, et al. (2002) The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100: 1215-1219.
42. Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszyńska A, Roliński J (2008) Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res 32: 225-233.
43. Yen Chong S, Lin YC, Czarneski J, Zhang M, Coffman F, et al. (2001) Cell cycle effects of IL-10 on malignant B-1 cells. Genes Immun 2: 239-247.
44. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, et al. (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97: 256-263.